Tissue distribution of sprifermin (recombinant human fibroblast growth factor 18) in the rat following intravenous and intra-articular injection
Summary: Objective: Fibroblast growth factor 18 (FGF18) is involved in chondrogenesis and articular cartilage repair. We investigated tissue distribution and pharmacokinetics of radioactive [3H]sprifermin, a recombinant human FGF18, in rats after a single intravenous (i.v.) or intra-articular (i.a....
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-09-01
|
| Series: | Osteoarthritis and Cartilage Open |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2665913120300571 |
| _version_ | 1818716146518458368 |
|---|---|
| author | C.H. Ladel L. Barbero S. Riva H. Guehring |
| author_facet | C.H. Ladel L. Barbero S. Riva H. Guehring |
| author_sort | C.H. Ladel |
| collection | DOAJ |
| description | Summary: Objective: Fibroblast growth factor 18 (FGF18) is involved in chondrogenesis and articular cartilage repair. We investigated tissue distribution and pharmacokinetics of radioactive [3H]sprifermin, a recombinant human FGF18, in rats after a single intravenous (i.v.) or intra-articular (i.a.) injection. Design: In two studies (48–96-h [n = 23] and 28-day [n = 12]), 35 male albino (Sprague Dawley) rats received single i.v. or i.a. dose [3H]sprifermin (0.24 mg/kg). Radioactivity was measured in blood, serum, and (in animals receiving i.a. administration) in the knee joint by liquid scintillation counting. Radioactivity in organs, tissues, and distribution in the whole body were measured with whole-body autoradiography. Results: After i.v. injection, radioactivity peaked in serum and whole blood after 4 and 24 h, respectively, with greater total radioactivity in serum. After i.a. injection, radioactivity peaked in serum and whole blood after 24 and 48 h, respectively; intact [3H]sprifermin was not detected in vena caval serum and systemic exposure was low, approximately 20% of that with i.v. injection. Following i.v. injection, radioactivity was mainly found in the liver, adrenal glands, kidney, and spleen; following i.a. injection, radioactivity was preferentially concentrated in articular cartilage after initial distribution in the joint capsule, and still evident in the joint after 28 days. Conclusions: After i.a. injection of [3H]sprifermin in rats, radioactivity was concentrated in the knee joint, particularly articular cartilage, with low levels in other investigated tissues. Systemic exposure to sprifermin was greater with i.v. than i.a. injection. Subsequent clinical investigation in patients with osteoarthritis has reported consistent results. |
| first_indexed | 2024-12-17T19:14:37Z |
| format | Article |
| id | doaj.art-91017ebb28ce4945b5c4ef4d880c9372 |
| institution | Directory Open Access Journal |
| issn | 2665-9131 |
| language | English |
| last_indexed | 2024-12-17T19:14:37Z |
| publishDate | 2020-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Osteoarthritis and Cartilage Open |
| spelling | doaj.art-91017ebb28ce4945b5c4ef4d880c93722022-12-21T21:35:47ZengElsevierOsteoarthritis and Cartilage Open2665-91312020-09-0123100068Tissue distribution of sprifermin (recombinant human fibroblast growth factor 18) in the rat following intravenous and intra-articular injectionC.H. Ladel0L. Barbero1S. Riva2H. Guehring3Merck KGaA, 64293, Darmstadt, Germany; Corresponding author. Clinical Biomarker & Diagnostics Lead, Translational Medicine, Global Development, Merck Serono Research, Merck KGaA, Frankfurter Straße 250, 64293, Darmstadt, Germany.Merck Serono Ivrea Research Centre, 10010, Colleretto Giacosa, ItalyMerck Serono Ivrea Research Centre, 10010, Colleretto Giacosa, ItalyMerck KGaA, 64293, Darmstadt, GermanySummary: Objective: Fibroblast growth factor 18 (FGF18) is involved in chondrogenesis and articular cartilage repair. We investigated tissue distribution and pharmacokinetics of radioactive [3H]sprifermin, a recombinant human FGF18, in rats after a single intravenous (i.v.) or intra-articular (i.a.) injection. Design: In two studies (48–96-h [n = 23] and 28-day [n = 12]), 35 male albino (Sprague Dawley) rats received single i.v. or i.a. dose [3H]sprifermin (0.24 mg/kg). Radioactivity was measured in blood, serum, and (in animals receiving i.a. administration) in the knee joint by liquid scintillation counting. Radioactivity in organs, tissues, and distribution in the whole body were measured with whole-body autoradiography. Results: After i.v. injection, radioactivity peaked in serum and whole blood after 4 and 24 h, respectively, with greater total radioactivity in serum. After i.a. injection, radioactivity peaked in serum and whole blood after 24 and 48 h, respectively; intact [3H]sprifermin was not detected in vena caval serum and systemic exposure was low, approximately 20% of that with i.v. injection. Following i.v. injection, radioactivity was mainly found in the liver, adrenal glands, kidney, and spleen; following i.a. injection, radioactivity was preferentially concentrated in articular cartilage after initial distribution in the joint capsule, and still evident in the joint after 28 days. Conclusions: After i.a. injection of [3H]sprifermin in rats, radioactivity was concentrated in the knee joint, particularly articular cartilage, with low levels in other investigated tissues. Systemic exposure to sprifermin was greater with i.v. than i.a. injection. Subsequent clinical investigation in patients with osteoarthritis has reported consistent results.http://www.sciencedirect.com/science/article/pii/S2665913120300571DistributionFGF18Intra-articularPharmacokineticsRat model |
| spellingShingle | C.H. Ladel L. Barbero S. Riva H. Guehring Tissue distribution of sprifermin (recombinant human fibroblast growth factor 18) in the rat following intravenous and intra-articular injection Osteoarthritis and Cartilage Open Distribution FGF18 Intra-articular Pharmacokinetics Rat model |
| title | Tissue distribution of sprifermin (recombinant human fibroblast growth factor 18) in the rat following intravenous and intra-articular injection |
| title_full | Tissue distribution of sprifermin (recombinant human fibroblast growth factor 18) in the rat following intravenous and intra-articular injection |
| title_fullStr | Tissue distribution of sprifermin (recombinant human fibroblast growth factor 18) in the rat following intravenous and intra-articular injection |
| title_full_unstemmed | Tissue distribution of sprifermin (recombinant human fibroblast growth factor 18) in the rat following intravenous and intra-articular injection |
| title_short | Tissue distribution of sprifermin (recombinant human fibroblast growth factor 18) in the rat following intravenous and intra-articular injection |
| title_sort | tissue distribution of sprifermin recombinant human fibroblast growth factor 18 in the rat following intravenous and intra articular injection |
| topic | Distribution FGF18 Intra-articular Pharmacokinetics Rat model |
| url | http://www.sciencedirect.com/science/article/pii/S2665913120300571 |
| work_keys_str_mv | AT chladel tissuedistributionofspriferminrecombinanthumanfibroblastgrowthfactor18intheratfollowingintravenousandintraarticularinjection AT lbarbero tissuedistributionofspriferminrecombinanthumanfibroblastgrowthfactor18intheratfollowingintravenousandintraarticularinjection AT sriva tissuedistributionofspriferminrecombinanthumanfibroblastgrowthfactor18intheratfollowingintravenousandintraarticularinjection AT hguehring tissuedistributionofspriferminrecombinanthumanfibroblastgrowthfactor18intheratfollowingintravenousandintraarticularinjection |